Irish psychedelic biotech firm GH Research PLC (NASDAQ:GHRS) reported its financial results for the second quarter ended June 30, 2024.
Q2 2024 Financial Highlights
Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023.
Research and development expenses were $9.8 million for the quarter ended June 30, 2024, compared to $7.2 million for the same quarter in 2023.
General and administrative expenses were $3.5 million for the quarter ended June 30, 2024, compared to $2.7 million for the same quarter in 2023.
The net loss was $10.4 million, or $0.20 loss per share, for the quarter that ...
